To our knowledge, the DARS/GDI2/P4HA2/TRUB1 that we identified are new GBM biomarkers because they have never been reported to be associated with the development and progression of GBM (Lu et al., 2020). This evidence concerns the gene P4HA2 and glioblastoma.